Comparison of cross-platform flow cytometry minimal residual disease evaluation in multiple myeloma using a common antibody combination and analysis strategy

Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma

(2014) J. Martinez-Lopez et al.   BLOOD

Front-Line Transplantation Program With Lenalidomide, Bortezomib, and Dexamethasone Combination As Induction and Consolidation Followed by Lenalidomide Maintenance in Patients With Multiple Myeloma: A Phase II Study by the Intergroupe Francophone du Myélome

(2014) Murielle Roussel et al.   JOURNAL OF CLINICAL ONCOLOGY

Comparable flow cytometry data can be obtained with two types of instruments, Canto II, and Navios. A GEIL study

(2013) Françoise Solly et al.   CYTOMETRY PART A

Prognostic Relevance of Treatment Response Measured by Flow Cytometric Residual Disease Detection in Older Patients With Acute Myeloid Leukemia

(2013) Sylvie D. Freeman et al.   JOURNAL OF CLINICAL ONCOLOGY

Minimal Residual Disease Assessed by Multiparameter Flow Cytometry in Multiple Myeloma: Impact on Outcome in the Medical Research Council Myeloma IX Study

(2013) Andy C. Rawstron et al.   JOURNAL OF CLINICAL ONCOLOGY

Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry

(2013) N Puig et al.   LEUKEMIA

Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders

(2013) M Ladetto et al.   LEUKEMIA

Minimal residual disease quantification using consensus primers and high-throughput IGH sequencing predicts post-transplant relapse in chronic lymphocytic leukemia

(2013) A C Logan et al.   LEUKEMIA

Association of response endpoints with survival outcomes in multiple myeloma

(2013) S Lonial et al.   LEUKEMIA

Flow cytometric differentiation of abnormal and normal plasma cells in the bone marrow in patients with multiple myeloma and its precursor diseases

(2013) Prashant R. Tembhare et al.   LEUKEMIA RESEARCH

A single-tube multiparameter seven-colour flow cytometry strategy for the detection of malignant plasma cells in multiple myeloma

(2013) N Robillard et al.   Blood Cancer Journal

Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia

(2012) M. Faham et al.   BLOOD

The Level of Minimal Residual Disease in the Bone Marrow of Patients with Multiple Myeloma before High-Dose Therapy and Autologous Blood Stem Cell Transplantation Is an Independent Predictive Parameter

(2011) Mark Korthals et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1

(2011) S. V. Rajkumar et al.   BLOOD

CD200 expression in plasma cell myeloma

(2011) Horatiu Olteanu et al.   BRITISH JOURNAL OF HAEMATOLOGY

Review of phenotypic markers used in flow cytometric analysis of MGUS and MM, and applicability of flow cytometry in other plasma cell disorders

(2010) Karthick R. M. Raja et al.   BRITISH JOURNAL OF HAEMATOLOGY

Beyond the CRAB Symptoms: A Study of Presenting Clinical Manifestations of Multiple Myeloma

(2010) Giampaolo Talamo et al.   Clinical Lymphoma Myeloma & Leukemia

Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study

(2008) M. J. Borowitz et al.   BLOOD

Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation

(2008) B. Paiva et al.   BLOOD

Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders

(2008) A. C. Rawstron et al.   HAEMATOLOGICA

Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma

(2008) R A Kyle et al.   LEUKEMIA